Latest News

Vanguard has plenty of great ETFs for investors seeking long-term growth, and these three are some of the best.

One is a profitable travel platform generating substantial cash. The other is a high-growth gaming company still burning through it. Their financial profiles could not be more different.

These three TSX stocks show the cash flow, moats and growth engines needed to double investor money by 2036.

Royalty receipts surged 14% as guidance raised for second consecutive quarter.

CEO Rothblatt calls H1 2026 "one of the most consequential periods" in company history.

Net sales hit $1.77 billion with 22.2% growth across all categories.

AI-native drug discovery advances neuroscience target with Roche while cutting cash guidance.

Net sales hit $6.6 billion, a record, as AI and infrastructure demand drive growth.

Market share gains offset sales decline as Perrigo completes Dermacosmetics divestiture.

The leading eVTOL company is making solid progress with its transportation-as-a-service business model.

Hims & Hers topped Q2 revenue estimates and raised guidance, but missed EPS forecasts, posted a wider net loss, and faces an FTC lawsuit, leaving Wall Street cautious with a Hold rating.

Grayson retains 126,429 shares worth about $7 million.

With only a few weeks left in Cook's tenure, let's look back on how well the company has done since he took the reins.

CIBC may still reward patient investors even after Canadian bank stocks surged, because earnings and buybacks can drive the next leg.

Kinder Morgan is adding more fuel to its dividend growth engine.

Ian Clark exercised stock options at $50.57 and immediately liquidated the position as the precision oncology company trades near $160 per share.

The stock may be down sharply, but don't count it out -- and the lower price makes it more attractive.

Cameco-backed Westinghouse Electric has filed confidentially for a potential IPO, a move that could ease Cameco's debt load and boost investor interest in nuclear stocks like NuScale Power and Fluor.

NASA has significantly more assets under management despite launching later, while ARKX concentrates 63% of its portfolio in industrials for defense-focused exposure.

It may seem like a good way to borrow, but it could easily backfire.

ASP Isotopes (NASDAQ:ASPI) outlined plans to expand its isotope production, radiopharmacy and helium businesses during Canaccord Genuity’s 46th Annual Growth Conference, with commercial deliveries of several stable isotopes targeted for the second half of 2026. Chief Commercial Officer Viktor Petko

Annexon (NASDAQ:ANNX) said it expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy, adding an independent 24-month dual primary endpoint alongside the study’s existing 15-month primary endpoint. The company said it remains confident in a planned fourth-quarter assessment of the

Humacyte (NASDAQ:HUMA) reported second-quarter commercial sales growth while outlining plans to expand adoption of its SYMVESS vascular repair product, submit a supplemental biologics license application for dialysis access and begin a first-in-human coronary bypass study. Commercial sales totaled

Boyd Group Services (TSE:BYD) reported second-quarter 2026 revenue above $1 billion for the first time, as the company expanded its footprint, integrated Joe Hudson’s Collision Center and advanced its Project 360 cost-transformation program. Revenue rose 30% year over year to $1.013 billion, while

Acumen Pharmaceuticals (NASDAQ:ABOS) said it remains on track to report top-line results late in 2026 from its Phase II ALTITUDE-AD study of sabirnetug, an investigational antibody designed to selectively target synaptotoxic amyloid-beta oligomers in early Alzheimer’s disease. Chief Executive Offic